Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceutical Research and Manufacturers of America (PhRMA)
Name	Pharmaceutical Research and Manufacturers of America
Abbreviation	PhRMA
Formation	1958
Type	Trade association
Headquarters	Washington, D.C.
Region served	United States
Membership	Major biopharmaceutical companies
Leader title	President and CEO

Contents

Pharmaceutical Research and Manufacturers of America (PhRMA) is a trade association representing biopharmaceutical companies involved in discovery, development, and commercialization of prescription medicines. It engages in advocacy, policymaking, industry research, and public relations on behalf of member firms in Washington, D.C., and on international stages including Geneva and Brussels. PhRMA interacts with regulatory and legislative bodies such as the Food and Drug Administration, United States Congress, World Health Organization, and European Medicines Agency while coordinating with partners like the American Medical Association, National Institutes of Health, Bill & Melinda Gates Foundation, and BIO (trade association).

History

PhRMA traces institutional roots to predecessor associations such as the Drug Manufacturers Association and the Association of American Medical Colleges in the mid-20th century, evolving through mergers and rebrandings during the administrations of Dwight D. Eisenhower and John F. Kennedy. In the 1980s and 1990s PhRMA expanded advocacy during legislative debates over the Orphan Drug Act, Bayh–Dole Act, and Medicare Part D, paralleling shifts in pharmaceutical R&D from companies like Pfizer, Merck & Co., Johnson & Johnson, and Eli Lilly and Company. The organization intensified policy campaigns around high-profile events including the passage of the Affordable Care Act and international negotiations at the World Trade Organization on the TRIPS Agreement.

PhRMA's governance includes a board of directors and executive leadership drawn from CEOs and senior officers of member firms such as Novartis, GlaxoSmithKline, AstraZeneca, Roche, and Bristol-Myers Squibb. Past leaders have engaged with figures from the U.S. Department of Health and Human Services, former cabinet officials from the Clinton administration and Bush administration, and policymakers from the European Commission and United Kingdom Department of Health and Social Care. Committees within PhRMA coordinate with external stakeholders including the National Academy of Sciences, Council on Foreign Relations, Kaiser Family Foundation, and think tanks like the Brookings Institution and Heritage Foundation.

PhRMA advocates for intellectual property protections exemplified by support for the Patent Act frameworks and extensions observed in disputes before the United States Court of Appeals for the Federal Circuit and the Supreme Court of the United States. It lobbies on drug pricing and reimbursement issues involving Medicare, Medicaid, and private insurers represented by groups such as the Blue Cross Blue Shield Association and America's Health Insurance Plans. In international fora PhRMA has participated in negotiations involving World Intellectual Property Organization, Trans-Pacific Partnership, and bilateral trade agreements with governments such as the United Kingdom, India, and China. The association also files amicus briefs in cases involving firms like Amgen and Gilead Sciences on patent disputes and regulatory interpretations.

PhRMA sponsors research reports and collaborates with institutions like Harvard University, Johns Hopkins University, Massachusetts Institute of Technology, Stanford University, and University of California, San Francisco to analyze R&D productivity, clinical trial design, and regulatory science. Initiatives include programs to streamline clinical trials with partners such as ClinicalTrials.gov, Duke University School of Medicine, Eli Lilly and Company, and trial networks tied to National Cancer Institute consortia and the American Society of Clinical Oncology. PhRMA-backed studies often cite metrics from industry analysts at IMS Health and economic assessments from groups like Deloitte and McKinsey & Company.

PhRMA has faced criticism and legal challenges from advocacy organizations including Public Citizen, AARP, Families USA, and media investigations by outlets like The New York Times, The Washington Post, and ProPublica over lobbying expenditures and advertising campaigns. Critics point to conflicts highlighted in congressional hearings led by members of the United States House Committee on Energy and Commerce and the United States Senate Committee on Finance, and to disputes involving whistleblowers associated with firms such as Valeant Pharmaceuticals and Turing Pharmaceuticals. Debates over patent evergreening, prescription drug pricing by companies like Martin Shkreli-associated entities, and settlements often invoke rulings from the Federal Trade Commission and antitrust litigation in the United States District Court system.

PhRMA's funding derives from membership dues, sponsorships, and program-specific contributions from multinational companies including Sanofi, Takeda Pharmaceutical Company, Bayer, Regeneron Pharmaceuticals, and AbbVie. Membership categories encompass major research-based firms, biotech companies, and affiliate organizations tied to trade groups such as Pharmaceutical Research and Manufacturers of America (PhRMA)-adjacent coalitions, industry-funded research foundations, and public affairs firms. Financial disclosures and lobbying reports are filed with entities like the Office of Congressional Ethics and the Federal Election Commission.

PhRMA-affiliated companies have played central roles in the development of therapies for conditions addressed by the National Institutes of Health and specialist societies such as the American Heart Association, American Diabetes Association, and American Cancer Society. The association's policy advocacy affects regulatory pathways overseen by the Food and Drug Administration, patent landscapes shaped by the United States Patent and Trademark Office, and reimbursement frameworks administered by Centers for Medicare & Medicaid Services. Debates over the balance between incentivizing innovation at companies like Moderna and BioNTech and ensuring patient access involve stakeholders such as patient advocacy groups, payers like UnitedHealth Group, and global health organizations like Gavi, the Vaccine Alliance.